S21-259 Isthmin Protein Therapeutics for the Treatment of Non-Alcoholic Fatty Liver Disease Stanford inventors in the Katrin Svensson laboratory have identified the protein Isthmin-1 (ISM1) as a treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Katrin Svensson Laetitia Voilquin